Skip to content

十亿分一

US · BLLN #2109 按市值排名 上市于 2025
98.12 -4.61 -4.49%
实时 - 追踪5344个代码 - 心跳于350秒前 · 2026-10-16 20:01

估值 各估值倍数与自身5年区间的对比

市净率 8.87 高于历史水平 第76百分位
5年平均 -0.33 · 在Diagnostics & Research中排名第32/40
市盈率 142.29 处于历史正常水平 第54百分位
5年平均 175.49 · 前瞻 104.02 · 在Diagnostics & Research中排名第18/19
市销率 11.98 处于历史正常水平 第36百分位
5年平均 13.74 · 前瞻 9.41 · 在Diagnostics & Research中排名第35/43

同业对比 Diagnostics & Research

公司 市值 市盈率(TTM) 市净率 股息率
十亿分一 (BLLN) 4.63B 138.39 8.63 0.00%
Thermo Fisher Scientific (TMO) 255.13B 37.14 4.84 0.26%
Danaher (DHR) 161.01B 40.68 3.06 0.63%
Natera (NTRA) 56.71B -291.44 31.13 0.00%
Agilent Technologies (A) 48.77B 34.12 6.62 0.59%
IDEXX Laboratories Inc (IDXX) 44.15B 39.38 27.38 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★☆☆☆ 合理价值86.36 经济护城河None 不确定性High

当前股价高于晨星合理价值估算12.0%。

合理价值

BillionToOne Inc earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 26% premium over our quantitative fair value estimate of $86.36 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 60.2 lies in the top 10% compared with global peers. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be overvalued.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.6%, a core component of profitability, falls in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:01:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

十亿分一 讨论区 0 条评论

发表评论